Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
Abroad (travel likely)RecruitingPHASE1
Conditions
Pediatric Disorder · Genetic Predisposition · Dystonia, Secondary · Dystonia · Cerebral Palsy, Dystonic-Rigid · Cerebral Palsy, Dyskinetic · Trihexyphenidyl Adverse Reaction · Pharmacogenomic Drug Interaction
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States
Contact: Principal Investigator (Rose Gelineau-Morel, MD)
Study leads
Rose Gelineau-Morel, MD
Principal Investigator
Children's Mercy Kansas City